Company news

Axsome Therapeutics, Inc. news in 2026

Axsome Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Axsome Therapeutics to Participate in Upcoming Investor Conferences

November 19, 2026

Axsome Therapeutics to Participate in Upcoming Investor Conferences

November 3, 2026

Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

November 2, 2026

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

October 7, 2026

Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer’s Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer’s Day

September 21, 2026

Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026

September 17, 2026

Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation

August 31, 2026

Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 10, 2026

Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy

July 15, 2026

Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10

July 14, 2026

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

July 7, 2026

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

June 26, 2026

Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month

June 18, 2026

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026

June 15, 2026

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

June 3, 2026

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

June 3, 2026

Axsome Therapeutics Partners with the Headache Alliance to Highlight the Impact of Migraine During Migraine and Headache Awareness Month

June 1, 2026

Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting

May 26, 2026

Axsome Therapeutics Recognizes Mental Health Month

May 7, 2026

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026

Axsome Therapeutics Hosts AUVELITY® FDA Approval Investor Event Featuring Expert Thought Leader

May 1, 2026

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease

April 30, 2026

Axsome Therapeutics to Report First Quarter 2026 Financial Results on May 4

April 7, 2026

Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions

March 31, 2026

Axsome Therapeutics Initiates CLARITY Phase 3 Trial of Solriamfetol in Adults with Major Depressive Disorder with Excessive Daytime Sleepiness Symptoms

February 23, 2026

Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

February 22, 2026

Axsome Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.

February 17, 2026

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

January 26, 2026

Axsome Therapeutics Initiates FORWARD Phase 3 Trial of AXS-14 for the Management of Fibromyalgia

January 14, 2026

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue

January 11, 2026

Calls in 2026

Decks in 2026